Effect of probucol therapy on plasma fatty acid composition during postprandial lipemia in hypertriglyceridemia

American Journal of Therapeutics

Volumn 4, Issue 7-8, 1997, Pages 247-254

  Corder, Clinton N ^a,b,e   Tavella, Marcelo ^b,c   McConathy, Walter ^b,d   Alaupovic, Petar ^b   Johnson, Myrna ^b  

^a Oklahoma Foundation for Cardiovascular Research   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^c UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^d UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

^e NONE   (United States)

Author keywords

Fatty acids; Hypertriglyceridemia; Postprandial; Probucol; Saturated; Unsaturated

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; ARACHIDONIC ACID; CHOLESTEROL; CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSATRIENOIC ACID; LINOLENIC ACID; LIPID; LIPOPROTEIN A; MYRISTIC ACID; OLEIC ACID; PALMITIC ACID; PHOSPHOLIPID; PROBUCOL; SATURATED FATTY ACID; STEARIC ACID; TRIACYLGLYCEROL; UNSATURATED FATTY ACID;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID COMPOSITION; MALE; PRIORITY JOURNAL; TEST MEAL;

EID: 0030860512     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199707000-00005     Document Type: Article

References (27)

1. Buckley MM-T, Gao KL, Price AH, Brogden RN: Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolemia. Drugs 1989;37: 761-800.
2. Atmeh RF, Stewart JM, Boag DE, Packard CJ, Lorimer AR, Shepard J: The hypolipidemic action of probucol: a study of its effects on high and low density lipoproteins. J Lipid Res 1983;24:588-595.
3. Parthasarathy W, Young SG, Witztum JL, Pittman RC, Steinberg D: Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 1986;77:641-644.
4. Bird JE, Milhoan K, Wilson CB, Young SG, Mindy GA, Parthasarathy S, Blantz RC: Ischemic acute renal failure and antioxidant therapy in the rat. The relation between glomerular and tubular dysfunction. J Clin Invest 1988; 81:1630-1678.
5. Carew TE, Schwenke DC, Steinberg D: Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 1987;84:7725-7729.
6. Holman R: Control of polyunsaturated acids in tissue lipids. J Am Coll Nutr 1986;5:183-211.
7. Bereziat G, Chambaz J, Trugnan G, Pepin D, Polonovski J: Turnover of phospholipid linoleic and arachidonic acids in human platelets from plasma lecithins. J Lipid Res 1978;19:495-500.
8. Wang CS, Kuksis A, Manganaro R: Studies on the substrate specificity of purified human milk lipoproteins lipase. Lipids 1982;17:278-284.
9. Spector A, Scanu A, Kaduce T, Figard P, Fless M, Czervionke R: Effect of human plasma lipoproteins on prostacyclin production by cultured endothelial cells. J Lipid Res 1985;26:288-297.
10. Miettinen TA, Naukkarinen V, Huttunen JK, Mattila S, Kumlin T: Fatty-acid composition of serum lipids predicts myocardial infarction. Br Med J 1982;285:993-996.
11. Tavella M, Corder CN, McConathy W: Effect of gemfibrozil on fatty acids in lipid fractions of plasma from patients with hypertriglyceridemia. J Clin Pharmacol 1993;33:35-39.
12. Lipid Research Clinics Program: The Manual of Laboratory Operations: Lipid and Lipoprotein Analysis. National Institutes of Health, Bethesda, MD, 1974. DHEW Publication No. NIH 75-628.
13. Alaupovic P, Lee DM, McConathy WJ: Studies on the composition and structure of plasma lipoproteins. Distribution of lipoprotein families in major density classes of normal human plasma lipoproteins. Biochim Biophys Acta 1972;260:689-707.
14. McConathy WJ, Koran E, Wieland H, Campos EM, Lee DM, Kloer HU, Alaupovic P: Evalulation of immunoaffinity chromotography for isolating human lipoproteins containing apoliproprotein B. J Chromatogr 1985;342: 47-66.
15. Statistical Analysis Systems (SAS) Users Guide. SAS Institute Inc. Cary, NC, 1982.
16. Reaven PD, Parthasarathy S, Beltz WF, Witztum JL: Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans. Arterioscler Thromb 1992;12:318-324.
17. Helve E, Tikkanen MJ: Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles. Atherosclerosis 1988;72:189-197.
18. Wetteran JR, Comba KA, Albers HW, Lamkin G, Stein EA, Barnhart RL, Chi EM, Jackson RL, Harmon JAK: Effects of probucol on plasma lipids, lipoproteins and parameters of high density lipoprotein metabolism. Horm Metab Res 1992;24:289-296.
19. Sundarajan V, Cooper DKC, Muchmore J, Manion CV, Liguori C, Zuhdi N, Novitzky D, Chen PN, Bourne DWA, Corder CN: Interaction of cyclosporine and probucol in heart transplant patients. Transplant Proc 1991; 23:2028-2032.
20. Brenner RR: Factors influencing fatty acid chain elongation and desaturation. In: The Role of Fats in Human Nutrition. (Eds. Vergroesen AJ, Crawford M), Academic Press, New York 1989, pp 46-79.
21. Borkman M, Storkin LH, Pan DA, Jenkins AB, Chisholm DJ, Campbell LV: The relation between insulin sensitivity and the fatty-acid composition of skeletal-muscle phospholipids. N Engl J Med 1993;328:238-244.
22. Brett D, Howling D, Morris L, James A: Specificity of the fatty acid desaturases: the conversion of saturated to monoenoic acids. Arch Biochem Biophys 1971;143:535-547.
23. Parthasarathy S, Khoo JC, Miller E, Barnett J, Witztum JL, Steinberg D: Low density lipoprotein rich in oleic acid is protected against oxidative modification: implications for dietary prevention of atherosclerosis. Proc Natl Acad Sci USA 1990;87:3894-3898.
24. Groot PHE, van Stiphout WAHJ, Krauss XH, Jansen H, van Tol A, van Ramshorst E, Chin-On S, Hofman A, Cresswell SR, Havekes L: Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler Thromb 1991;11:653-662.
25. Baudet MF, Esteva O, Lasserre M, Jacotot B: Dietary modifications of low-density lipoprotein fatty acids in humans: their effect on low-density lipoprotein-fibroblast interactions. Clin Physiol Biochem 1986;4:173-186.
26. Kayden HJ, Karmen A, Dumot A: Alterations in the fatty acid composition of human lymph and serum lipoproteins by single feedings. J Clin Invest 1963;42:1373-1381.
27. Whyte M, Karmen A, Goodman DS: Fatty acid esterification and chylomicron formation during fat absorption. 2. Phospholipids. J Lipid Res 1963;4:322-329.